Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

By Rose C.  

Breast Cancer Research and Treatment, Vol. 61, Iss. 2, 2000-05 ,pp. : 103-110

Springer Publishing Company

Access to resources Recommend Favorite

Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

By Herk-Sukel Myrthe  

Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. : 843-851

Springer Publishing Company

Access to resources Recommend Favorite

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer-a randomised study with more than 10 years follow-up from the danish breast cancer cooperative gr

By Andersson M.   Lindegaard Madsen E.   Overgaard M.   Rose C.   Dombernowsky P.   Mouridsen H.T.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 39-46

Elsevier

Access to resources Recommend Favorite

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 135-136

Informa Healthcare

Access to resources Recommend Favorite